Definitive Radiotherapy for Cervical and Upper Thoracic Esophageal Cancer (ChC&UES): A Multi-center Real World Study

Launched by HEBEI MEDICAL UNIVERSITY FOURTH HOSPITAL · Jun 27, 2024

Keywords

ClinConnect Summary

This clinical trial is studying how effective and safe radical radiation therapy (sometimes combined with chemotherapy) is for treating cervical and upper thoracic esophageal cancer, which is a type of cancer located in the upper part of the esophagus. This research is important because there isn't a lot of information available about the best ways to treat this specific cancer. The trial is currently recruiting participants aged 18 and older who have been diagnosed with esophageal cancer in the cervical or upper thoracic area and who cannot or choose not to undergo surgery. To qualify, patients should not have cancer that has spread to other parts of the body and should be receiving a specific type of radiation treatment.

Participants in this study can expect to receive conventional radiation therapy, where they will have daily sessions aimed at delivering a precise dose of radiation to the tumor. The trial aims to gather important data on how well this treatment works and how patients tolerate it, helping to improve future care for others with this type of cancer. If you're considering joining this study, it's a chance to contribute to valuable research while receiving treatment for your condition.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Age 18 and older.
• • 2. Confirmation of esophageal cancer through histopathology or cytology.
• • 3. Primary tumor location within the cervical or upper thoracic segment, extending from the upper esophageal sphincter to the azygos vein.
• • 4. Absence of distant metastasis.
• • 5. Patients unable or unwilling to undergo surgical treatment for various reasons.
• • 6. Receipt of radical radiotherapy as the first-line treatment, with or without chemotherapy, immunotherapy, or targeted therapy.
• • 7. Undergoing conventional radiation therapy (1.8-2.0Gy per session, once per day).
• • 8. Receiving 3DCRT or IMRT radiotherapy.
• • 9. Availability of complete radiotherapy prescription dose information and follow-up records.
• Exclusion Criteria:
• • 1. Receipt of radiation dose below 50Gy.
• • 2. History of other malignancies (except for cured cancer in situ and malignancies cured for over 5 years) or laryngeal invasion.
• • 3. Diagnosis of double primary esophageal cancer.
• • 4. Prior chest radiation therapy within the past 5 years.
• • 5. Recurrent or metastatic esophageal cancer.
• • 6. Receipt of 2D radiotherapy, large fractionation, or hyper-fractionation radiotherapy.
• • 7. Patients with incomplete radiotherapy dose and follow-up data.